Upregulation of MTA2 was revealed in many cancers, such as cervical cancer, hepatocellular carcinoma, pancreatic ductal adenocarcinoma, contributing an increasingly aggressive phenotype 33. This evidence concerns the gene MTA2 and cervical carcinoma.